1227 Eliminating the immunotoxicity of interleukin-12 through protease-sensitive masking

作者
Jun Ishihara,Aslan Mansurov,Jeffrey A. Hubbell
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:: A1272-A1272
标识
DOI:10.1136/jitc-2022-sitc2022.1227
摘要

Background Checkpoint inhibitor (CPI) immunotherapy demonstrates modest efficacy against immunologically ‘cold’ or immune-excluded tumors, therefore needs another approach for majority of patients. Although interleukin-12 (IL-12) is a promising antitumor cytokine that enables activation and recruitment of immune cells into tumors, its widespread use in the clinic has been hindered due to severe immune-related adverse events (irAEs). An ideal IL-12 therapy would restrict the proinflammatory effects of IL-12 to the tumor site, while limiting its exposure in the periphery. Methods Here, we solved the IL-12 toxicity challenge by exploiting the preferential overexpression of proteases (Matrix Metalloproteinases, Serine Proteases) in the tumor to engineer tumor-selective, masked IL-12. A IL-12RB1 receptor-based masking domain was fused to IL-12 p35 domain via a protease-cleavable linker.1 Results Recombinant fusion of masking domain to IL-12 prevented IL-12 from signaling systemically, whereas proteolytic cleavage of the linker domain by tumor-associated enzymes restored the biological activity of IL-12. We demonstrate that intravenously (i.v.) administered, masked IL-12 produces strong therapeutic effects through remodeling the immune-suppressive microenvironment and renders CPI-resistant tumors responsive, while systemic irAEs are eliminated, boosting the therapeutic index of this promising cytokine. In several solid tumour models, the therapeutic effects of masked IL12 were similar to its unmasked wild-type form, yet its toxicity was as low as saline injections. Masked IL-12 synergised with anti-PD-1 antibody for efficacy. We found that addition of human tumour lysates, and not adjacent healthy tissue lysates, cleaved off the mask, induced significant IFNy production and STAT4 phosphorylation, similar to wild-type IL-12. We made fully humanized masked IL-12 molecule already. Conclusions Masking approach to IL-12 may solve the toxicity issue of IL-12 observed in 1990s clinical trials, while maintaining extremely high anti-tumor effects in immunologically cold tumors (figure 1). Reference Mansurov A,...Ishihara J, Hubbell JA. Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker. Nature Biomedical Engineering, May 2022 Ethics Approval All animal experiments performed in this work were approved by the Institutional Animal Care and Use Committee of the University of Chicago.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lili完成签到 ,获得积分10
5秒前
锂电说完成签到 ,获得积分10
6秒前
夜未央完成签到 ,获得积分10
7秒前
bellapp完成签到 ,获得积分10
7秒前
Shandongdaxiu完成签到 ,获得积分10
9秒前
9秒前
朴素的嚓茶完成签到,获得积分10
12秒前
阳光的易形完成签到,获得积分10
15秒前
观澜完成签到 ,获得积分10
16秒前
万能图书馆的应助被taotao采纳,获得30
19秒前
文献就着酒灵感如泉涌完成签到,获得积分10
20秒前
科学心完成签到,获得积分10
23秒前
Akim的应助被维维采纳,获得10
27秒前
cjl完成签到 ,获得积分10
33秒前
34秒前
taotao发布了新的文献求助30
38秒前
维维完成签到,获得积分10
39秒前
40秒前
维维发布了新的文献求助10
45秒前
47秒前
wuqs完成签到,获得积分10
51秒前
岁大爷发布了新的文献求助10
51秒前
不安碧灵完成签到,获得积分10
52秒前
呆萌芙蓉完成签到 ,获得积分10
53秒前
樱岛芳子完成签到 ,获得积分10
54秒前
CY完成签到,获得积分0
56秒前
粗犷的骁完成签到,获得积分10
57秒前
爱宁完成签到 ,获得积分10
57秒前
xiaohansan完成签到 ,获得积分10
59秒前
Evelyn完成签到,获得积分10
1分钟前
记得哄小孩完成签到,获得积分10
1分钟前
Jessie完成签到 ,获得积分10
1分钟前
1分钟前
yhjyhjyhj完成签到 ,获得积分10
1分钟前
跳跃的枫完成签到,获得积分10
1分钟前
温暖完成签到 ,获得积分10
1分钟前
kingfly2010完成签到,获得积分10
1分钟前
chengxue完成签到,获得积分10
1分钟前
王亚楠完成签到 ,获得积分10
1分钟前
SRD完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173289
求助须知:如何正确求助?哪些是违规求助? 9565594
关于积分的说明 21780596
捐赠科研通 7767485
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476714